In 2003, the U.S. government obtained a notable patent for the use of cannabinoids as antioxidants and neuroprotectants. The application was filed as early as 1999 by researchers at the U.S. National Institutes of Health (NIH).
This concerns US Patent 6,630,507, titled Cannabinoids as antioxidants and neuroprotectantsThe U.S. Department of Health and Human Services (HHS) became the owner of the patent.
Protection of nerve cells
The patent describes that cannabinoids may offer protection against damage to nerve cells. This includes neurological disorders such as Alzheimer's and Parkinson's, but also damage resulting from a stroke and HIV-related dementia.
CBD also plays an important role in this. According to the patent, this cannabinoid has antioxidant properties without the same psychoactive effect as THC.
Striking contrast with American drug policy
The patent is particularly notable due to US cannabis policy. Cannabis was simultaneously listed federally in Schedule I, the strictest category under the Controlled Substances Act. This category is intended for drugs for which there is no accepted medical use according to federal classification.
However, this does not mean that the US government thereby officially recognized cannabis as a medicine as a whole. A patent protects a specific invention or application and is not a medical approval.
Ready to see how Snowflake works?
The widely shared claim that the US government “patented cannabis as medicine” is therefore too simplistic. However, a US government agency did patent specific potential medical applications of cannabinoids decades ago. It is precisely in combination with the strict federal cannabis policy that this patent makes for a notable chapter in American cannabis history.
Source: dea.gov en patents.google
